Stock Movers Palantir Slides, Novo Boosts Bid, Spotify Beats on Users
4 snips
Nov 4, 2025 Palantir's shares dip after a staggering 170% rise this year, despite impressive quarterly results and a raised forecast. Skepticism grows among investors about its valuation amidst AI hype. Novo Nordisk intensifies the bidding for Metsera, stirring excitement in the obesity drug market. Spotify surprises with a jump in active users and revenue, allaying fears about leadership changes, even as ad revenue takes a hit. A whirlwind of key market actions unfolds!
AI Snips
Chapters
Transcript
Episode notes
Palantir's Strong Results, Stretched Valuation
- Palantir keeps beating expectations but its valuation is extremely high relative to peers.
- Trailing price-to-sales sits near 85, prompting concerns about a stretched AI-driven premium.
High-Profile Bears Join The Conversation
- Michael Burry's Scion disclosed bearish wagers on NVIDIA and Palantir, adding high-profile skepticism.
- Morgan Stanley and Goldman Sachs executives also voiced valuation concerns amid the rally.
Obesity Drugs Spark Intense M&A Battle
- Novo Nordisk and Pfizer raised bids for obesity startup MedSera, driving MedSera shares sharply higher.
- The takeover fight highlights how critical obesity drugs have become to big pharma strategies.